Collaboration to leverage Umoja's VivoVecTM gene delivery platform and AbbVie's expertise in oncology to develop in-situ generated chimeric antigen receptor (CAR)-T cell therapy candidates NORTH CHICAGO, Ill. and SEATTLE, Jan. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV), and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja's propriet ...